Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

New Clinical Perspectives in the Management of Myelofibrosis

Access Activity

Overview / Abstract:


Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treatment options, therapeutic goals are focused on slowing progression and maintaining quality of life. Median overall survival varies across risk groups, ranging from 15.4 years for patients with low-risk disease to only 1.3 years for those with high-risk disease. Furthermore, up to 20% of myelofibrosis cases transform to acute myeloid leukemia, where the 5-year overall survival rate is only 27%.


Hematology/oncology physicians, oncology advanced practitioners, and other health care professionals involved in the management of patients with myelofibrosis.


Upon completion of this activity, participants should be able to:

1. Assess predictive and prognostic markers that can rationally inform personalized care planning in myelofibrosis
2. Apply emerging data in therapeutic strategies to improve survival and quality of life in patients with myelofibrosis
3. Discuss the implications that research advances in myelofibrosis may have for future clinical practice


Sep 30, 2020


Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Srdan Verstovsek, MD, PhD (Chairperson)
Professor, Department of Leukemia
The University of Texas

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Celgene and Incyte.

Keywords / Search Terms

i3 Health i3 Health, myelofibrosis, myeloproliferative neoplasms, MPN, MPNs, primary myelofibrosis, JAK inhibitors, CME, free CME, MOC, ILNA points, ILNA, hematology Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.